Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer’s disease with standardized uptake value peak-alignment (SUVP) normalization

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2018-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-018-4040-1PMID 29704038PMCID PMC6174003
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia

  2018cited by this paper
• Comparison of multiple tau‐PET measures as biomarkers in aging and Alzheimer's disease

  2017cited by this paper
• Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data

  2017cited by this paper
• Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings

  2017cited by this paper
• 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy

  2017cited by this paper
• Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

  2017cited by this paper
• Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351

  2016cited by this paper
• Tau positron emission tomographic imaging in aging and early Alzheimer disease

  2016cited by this paper
• 18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease

  2016cited by this paper
• An autoradiographic evaluation of AV-1451 Tau PET in dementia

  2016cited by this paper
• Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.

  2016cited by this paper
• Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition

  2016cited by this paper
• Cortical Laminar Binding of PET Amyloid and Tau Tracers in Alzheimer Disease

  2015cited by this paper
• 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

  2015cited by this paper
• The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

  2015cited by this paper
• Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies

  2013cited by this paper
• Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease

  2013cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Reducing between scanner differences in multi-center PET studies

  2009cited by this paper
• Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule‐associated protein tau

  2006cited by this paper
• Tau protein as a differential biomarker of tauopathies.

  2005cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

  1997cited by this paper
• The Mean, Median, and Mode of Unimodal Distributions:A Characterization

  1997cited by this paper
• Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

  1994cited by this paper

• Changes in glucose metabolism in essential tremor: within and beyond the cerebello-thalamo-cortical circuit

  2025cites this paper
• Impaired sleep is associated with tau deposition on 18F-flortaucipir PET and accelerated cognitive decline, accounting for medications that affect sleep.

  2024cites this paper
• Examining iron‐related off‐target binding effects of 18F‐AV1451 PET in the cortex of Aβ+ individuals

  2024cites this paper
• [1-11C]-Butanol Positron Emission Tomography reveals an impaired brain to nasal turbinates pathway in aging amyloid positive subjects

  2024cites this paper
• Peripheral immune cell imbalance is associated with cortical beta-amyloid deposition and longitudinal cognitive decline

  2023cites this paper
• The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET

  2023cites this paper
• Machine learning application for classification of Alzheimer's disease stages using 18F-flortaucipir positron emission tomography

  2023cites this paper
• Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study

  2023cites this paper
• A 19-Year-Old Adolescent with Probable Alzheimer’s Disease

  2022cites this paper
• Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia

  2022cites this paper
• Overview of tau PET molecular imaging

  2022cites this paper
• GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network

  2022cites this paper
• Targeting PSEN1 by lnc-CYP3A43-2/miR-29b-2-5p to Reduce β Amyloid Plaque Formation and Improve Cognition Function

  2022cites this paper
• Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

  2021cites this paper
• Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer’s disease and supporting differential diagnosis

  2021cites this paper
• Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.

  2019cites this paper
• Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment

  2019cites this paper